Contact Us
Phase-Xs | Biologics & Biosimilars | Coherent Market Insights

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

COVID-19 infection is caused by the novel SARS-CoV-2, which is a member of single stranded RNA coronavirus family. Few of the common symptoms observed in COVID-19 patients include dry cough, fever, and fatigue while some less common symptoms include muscle pain, nausea, diarrhea, loss of smell, vomiting, chills, and conjunctivitis. Sometimes, severe symptoms such as shortness of breath, confusion, loss of appetite, and others may be observed in the COVID-19 patients. According to the World Health Organization, people above the age of 60 years, and those already suffering from any kind of co-morbid condition such as cancer, hypertension, heart diseases, diabetes, and others are at higher risk of getting infected with severe COVID-19 infection.

The global COVID-19 rapid diagnostic test market is estimated to be valued at US$ 3,422.1 million in 2021 and is expected to exhibit a CAGR of 12.2% over the forecast period (2021-2028).

Figure 1. Global COVID-19 Rapid Diagnostic Test Market Share (%), By Region, 2021

COVID-19 Rapid Diagnostic Test  | Coherent Market Insights

The increasing cases of COVID-19 is expected to drive the growth of the global COVID-19 rapid diagnostic test market over the forecast period.

For instance, according to the COVID-19 Weekly Epidemiological Update published by the World Health Organization (WHO) on July 27, 2021, it is estimated that the global number of COVID-19 cases will exceed 200 million till mid-August. WHO also stated, that there was a sharp increase of 21% in the number of deaths due to COVID-19 as compared to previous week, i.e. July 12, 2021 to July 18, 2021.

request-sample

COVID-19 Rapid Diagnostic Test Market Report Coverage

Report Coverage Details
Base Year: 2019 Market Size in 2021: US$ 3,422.1 Mn
Historical Data for: 2016 to 2019 Forecast Period: 2021 to 2028
Forecast Period 2021 to 2028 CAGR: 12.2% 2028 Value Projection: US$ 7,660.2 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Product Type: Instruments, Reagents & Kits
  • By Sample Type: Nasopharyngeal (NP) Swabs, Oropharyngeal (OP) Swabs, Nasal Swabs, Blood, Others (others include Saliva)
  • By Test Type: Molecular Testing, Antigen-based Testing, Antibody Testing, Others (others include CRISPR and Biosensors)
  • By End User: Hospital & Clinic, Laboratories & Diagnostics Centers, Others
Companies covered:

Abbott, F. Hoffmann-La Roche AG, Cardinal Health, Alfa Scientific Designs Inc., Danaher, Bio-Rad Laboratories Inc., Artron Laboratories Inc., Trinity Biotech, bioMérieux SA, Creative Diagnostics, ACON Laboratories Inc., Thermo Fisher Scientific, Inc., Sight Diagnostics Ltd., Meridian Bioscience, Quest Diagnostics, Perkin Elmer, Inc., Luminex Corporation, Laboratory Corporation of America Holdings, and Veredus Laboratories

Growth Drivers:
  • Rising cases of COVID-19 infection
  • Increasing product launches and approvals
  • Increasing research and development activities by the market players
Restraints & Challenges:
  • Product recall
  • Shortage of skilled healthcare professionals 
  • Less efficacy of rapid COVID-19 diagnostic tests as compared to laboratory setting

Figure 2. Global COVID-19 Rapid Diagnostic Test Market Value (US$ Mn), By Product Type, 2021

COVID-19 Rapid Diagnostic Test  | Coherent Market Insights

The increasing research and development activities for the development of novel diagnostics for the diagnosis of COVID-19 is expected to drive the market growth over the forecast period.

Key players operating in the market are focusing on launching of new diagnostics for COVID-19 detection and submitting application for its approval, which is expected to drive growth of the global COVID-19 rapid diagnostic test market over the forecast period.

For instance, in May 2020, Sherlock Biosciences, a Cambridge based biotechnology company received the U.S. Food and Drug Administration (FDA) approval for emergency authorization of its CRISPR-based COVID-19 diagnostic test, thus making it the first ever COVID-19 test using CRISPR technology.

Furthermore, in September 2020, Mammoth Biosciences, a U.S. based biotechnology company received emergency use authorization by the U.S. FDA for its SARS-CoV-2 DETECTR Reagent Kit which is based on CRISPR technology. Moreover, in September 2020, the U.S. FDA granted emergency use status to MiraDx, a U.S. based molecular genetics company for its SARS-CoV-2 RT-PCR assay used for detection of COVID-19.

Newer innovations in the field of COVID-19 diagnostics would propel the global COVID-19 rapid diagnostic test market growth over the forecast period. For instance, in March 2021, Roche Holding AG, a Swiss pharmaceutical company, launched its new rapid antigen nasal kit for quicker diagnosis of COVID-19 infection. This COVID-19 diagnosis kit gives results within 15 minutes of sample collection and ensures minimum contact between the healthcare professional and the suspected COVID-19 positive patient as the sample is collected from nasal secretions rather than nasopharyngeal.

Global COVID-19 Rapid Diagnostic Test Market – Impact of Coronavirus (Covid-19) Pandemic

Coronavirus (COVID-19) outbreak was first reported on December 31, 2019, in Wuhan, China. The World Health Organization declared COVID-19, as pandemic on March 11, 2020. According to the Coronavirus (COVID-19) Weekly Epidemiological Update by the World Health Organization, over 190,169,833 cases and 4,086,000 deaths due to Coronavirus (COVID-19) were reported till July 18, 2021, across the globe. During this COVID-19 pandemic, pharmaceutical business, clinical tool companies, and likewise biotechnology firms are facing difficulties that are occurring from the interruption in supply chains and the demand to transform service processes. However, the COVID-19 pandemic is expected to positively impact the COVID-19 rapid diagnostic test market, owing to rising number of product launches and approvals.

For instance, in July 2020, the Indian government launched a cost-effective COVID-19 test, which was developed by researchers at Indian Institute of Technology (IIT), Delhi. This COVID-19 test is a swab based RT-PCR test that gives results within three hours and is priced at INR 399 (US$ 5.34). Furthermore, in June 2021, IIT- Delhi launched an even cheaper version COVID-19 test which is priced at INR 50 (US$ 0.67). This is expected to boost the testing rates in rural areas as well and thus fuel the growth of global COVID-19 rapid diagnostic test market.

Moreover, in March 2020, Abbott, a U.S. based medical device company launched ID NOW COVID-19 test which is a molecular based point-of-care diagnostic test for detection of SARS-CoV-2 that delivers results in five to 13 minutes. For instance, in April 2021, Abbott received emergency use authorization by the U.S. FDA for its new rapid antigen COVID-19 self-testing kit called Panbio. Furthermore, on July 12, 2021, Abbott launched Panbio to be used in diagnosis of COVID-19 infection.

Global COVID-19 Rapid Diagnostic Test Market Restraint

Product recalls, shortage of skilled healthcare professionals, less efficacy of rapid COVID-19 diagnostic tests as compared to laboratory setting are the factors that are expected to hinder growth of the global COVID-19 rapid diagnostic test market over the forecast period. For instance, in May 2020, India recalled rapid-antibody COVID-19 testing kits from two Chinese in-vitro diagnostics companies namely Guangzhou Wondfo Biotech Co. and Zhuhai Livzon Diagnostics, Inc., due to low accuracy and inconsistent results delivered by the COVID-19 test kits.

Key Players

Major players operating in the global COVID-19 rapid diagnostic test market include Abbott, F. Hoffmann-La Roche AG, Cardinal Health, Alfa Scientific Designs Inc., Danaher, Bio-Rad Laboratories Inc., Artron Laboratories Inc., Trinity Biotech, bioMérieux SA, Creative Diagnostics, ACON Laboratories Inc., Thermo Fisher Scientific, Inc., Sight Diagnostics Ltd., Meridian Bioscience, Quest Diagnostics, Perkin Elmer, Inc., Luminex Corporation, Laboratory Corporation of America Holdings, and Veredus Laboratories

Coronavirus is a family of enveloped, single stranded RNA viruses that infect humans, chimpanzees, other mammals, and avian species. Coronavirus generally causes gastrointestinal and respiratory infections. The severity of infection caused by Coronavirus can range from common cold to highly severe MERS (Middle East Respiratory Syndrome). SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus) is a novel Coronavirus which has been identified in early 2020 by the World Health Organization. COVID-19 infection caused by SARS-CoV-2, emerged in December 2019 and is highly transmissible and life-threatening. It takes around two to fourteen days for a person to show symptoms after the exposure to the virus. Symptoms may range from common cold like symptoms such as cough, congestion or runny nose, headache, and fever to severe life-threatening conditions such as kidney failure, stroke, heart attack, and others. However, some people suffering from COVID-19 infection may not show symptoms at all and still be contagious to healthy people. Thus, it is essential to test for COVID-19 infection so that the spread of COVID-19 can be controlled.

Market Dynamics

The increasing incidence of COVID-19 cases, rising research and development activities for the development of novel diagnostic methods for the diagnosis of COVID-19, and increasing adoption of inorganic growth strategies such as acquisitions and collaborations by key players operating in the market, are the major factors that are expected to drive growth of the global COVID-19 rapid diagnostic test market over the forecast period.

For instance, in November 2020, Tata Medical and Diagnostics, an Indian healthcare company launched its new product TataMD CHECK, which is a nasal swab test that is able to diagnose COVID-19 within 90 minutes. Moreover, in January 2021, iMFLUX, Inc., a U.S. based molding company entered into a partnership with Rhinostics, Inc., a Harvard University startup, to develop polypropylene COVID-19 nasal swab. These nasal swabs are cost effective and allow easy collection of nasal secretion from suspected COVID-19 patients.

Key features of the study:

  • This report provides in-depth analysis of the global COVID-19 rapid diagnostic test market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2021–2028), considering 2020 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global COVID-19 rapid diagnostic test market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include Abbott, F. Hoffmann-La Roche AG, Cardinal Health, Alfa Scientific Designs Inc., Danaher, Bio-Rad Laboratories Inc., Artron Laboratories Inc., Trinity Biotech, bioMérieux SA, Creative Diagnostics, ACON Laboratories Inc., Thermo Fisher Scientific, Inc., Sight Diagnostics Ltd., Meridian Bioscience, Quest Diagnostics, Perkin Elmer, Inc., Luminex Corporation, Laboratory Corporation of America Holdings, and Veredus Laboratories
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global COVID-19 rapid diagnostic test market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global COVID-19 rapid diagnostic test market

Detailed Segmentation:

  • Global COVID-19 Rapid Diagnostic Test Market, By Product Type:
    • Instruments
    • Reagents & Kits
  • Global COVID-19 Rapid Diagnostic Test Market, By Sample Type:
    • Nasopharyngeal (NP) Swabs
    • Oropharyngeal (OP) Swabs
    • Nasal Swabs
    • Blood
    • Others (others include Saliva)
  • Global COVID-19 Rapid Diagnostic Test Market, By Test Type:
    • Molecular Testing
    • Antigen-based Testing
    • Antibody Testing
    • Others (others include CRISPR and Biosensors)
  • Global COVID-19 Rapid Diagnostic Test Market, By End User:
    • Hospital & Clinic
    • Laboratories & Diagnostics Centers
    • Others
  • Global COVID-19 Rapid Diagnostic Test Market, By Region:
    • North America
      • By Product Type
        • Instruments
        • Reagents & Kits
      • By Sample Type
        • Nasopharyngeal (NP) Swabs
        • Oropharyngeal (OP) Swabs
        • Nasal Swabs
        • Blood
        • Others (others include Saliva)
      • By Test Type
        • Molecular Testing
        • Antigen-based Testing
        • Antibody Testing
        • Others (others include CRISPR and Biosensors)
      • By End User
        • Hospital & Clinic
        • Laboratories & Diagnostics Centers
        • Others
      • By Country
        • U.S.
        • Canada
    • Latin America
      • By Product Type
        • Instruments
        • Reagents & Kits
      • By Sample Type
        • Nasopharyngeal (NP) Swabs
        • Oropharyngeal (OP) Swabs
        • Nasal Swabs
        • Blood
        • Others (others include Saliva)
      • By Test Type
        • Molecular Testing
        • Antigen-based Testing
        • Antibody Testing
        • Others (others include CRISPR and Biosensors)
      • By End User
        • Hospital & Clinic
        • Laboratories & Diagnostics Centers
        • Others
      • By Country
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Product Type
        • Instruments
        • Reagents & Kits
      • By Sample Type
        • Nasopharyngeal (NP) Swabs
        • Oropharyngeal (OP) Swabs
        • Nasal Swabs
        • Blood
        • Others (others include Saliva)
      • By Test Type
        • Molecular Testing
        • Antigen-based Testing
        • Antibody Testing
        • Others (others include CRISPR and Biosensors)
      • By End User
        • Hospital & Clinic
        • Laboratories & Diagnostics Centers
        • Others
      • By Country
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Product Type
        • Instruments
        • Reagents & Kits
      • By Sample Type
        • Nasopharyngeal (NP) Swabs
        • Oropharyngeal (OP) Swabs
        • Nasal Swabs
        • Blood
        • Others (others include Saliva)
      • By Test Type
        • Molecular Testing
        • Antigen-based Testing
        • Antibody Testing
        • Others (others include CRISPR and Biosensors)
      • By End User
        • Hospital & Clinic
        • Laboratories & Diagnostics Centers
        • Others
      • By Country
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Product Type
        • Instruments
        • Reagents & Kits
      • By Sample Type
        • Nasopharyngeal (NP) Swabs
        • Oropharyngeal (OP) Swabs
        • Nasal Swabs
        • Blood
        • Others (others include Saliva)
      • By Test Type
        • Molecular Testing
        • Antigen-based Testing
        • Antibody Testing
        • Others (others include CRISPR and Biosensors)
      • By End User
        • Hospital & Clinic
        • Laboratories & Diagnostics Centers
        • Others
      • By Country
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Product Type
        • Instruments
        • Reagents & Kits
      • By Sample Type
        • Nasopharyngeal (NP) Swabs
        • Oropharyngeal (OP) Swabs
        • Nasal Swabs
        • Blood
        • Others (others include Saliva)
      • By Test Type
        • Molecular Testing
        • Antigen-based Testing
        • Antibody Testing
        • Others (others include CRISPR and Biosensors)
      • By End User
        • Hospital & Clinic
        • Laboratories & Diagnostics Centers
        • Others
      • By Country/Region
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Abbott*
      • Company Overview
      • Material Portfolio
      • Financial Performance
      • Key Highlights
      • Market Strategies
    • F. Hoffmann-La Roche AG
    • Cardinal Health
    • Alfa Scientific Designs Inc.
    • Danaher
    • Bio-Rad Laboratories Inc.
    • Artron Laboratories Inc.
    • Trinity Biotech
    • bioMérieux SA
    • Creative Diagnostics
    • ACON Laboratories Inc.
    • Thermo Fisher Scientific, Inc.
    • Sight Diagnostics Ltd.
    • Meridian Bioscience
    • Quest Diagnostics
    • Perkin Elmer, Inc.
    • Luminex Corporation
    • Laboratory Corporation of America Holdings
    • Veredus Laboratories

 “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Product Type
      • Market Snippet, By Sample Type
      • Market Snippet, By Test Type
      • Market Snippet, By End User
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Pipeline Analysis
    • PEST Analysis
    • Regulatory Scenario
    • Market Trends
    • Key Highlights
    • Reimbursement Scenario
    • Mergers & Acquisitions
  4. Global COVID-19 Rapid Diagnostic Test Market – Impact of Coronavirus (Covid-19) Pandemic
    • Economic Impact
    • Impact on Clinical Trials and Drug Development
    • Government Initiatives
  5. Global COVID-19 Rapid Diagnostic Test Market, By Product Type, 2017 – 2028, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, 2018 – 2028
      • Segment Trends
    • Instruments
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
    • Reagents & Kits
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  6. Global COVID-19 Rapid Diagnostic Test Market, By Sample Type, 2017 – 2028, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, 2018 – 2028
      • Segment Trends
    • Nasopharyngeal (NP) Swabs
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
    • Oropharyngeal (OP) Swabs
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
    • Nasal Swabs
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
    • Blood
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
    • Others (others include Saliva)
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  7. Global COVID-19 Rapid Diagnostic Test Market, By Test Type, 2017 – 2028, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, 2018 – 2028
      • Segment Trends
    • Molecular Testing
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
    • Antigen-based Testing
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
    • Antibody Testing
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
    • Others (others include CRISPR and Biosensors)
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  8. Global COVID-19 Rapid Diagnostic Test Market, By End User, 2017 – 2028, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, 2018 – 2028
      • Segment Trends
    • Hospital & Clinic
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
    • Laboratories & Diagnostics Centers
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  9. Global COVID-19 Rapid Diagnostic Test Market, By Region, 2017 – 2028, (US$ Mn)
    • Introduction
      • Market Share Analysis, By Region, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, For Regions, 2018–2028
    • North America
      • Market Size and Forecast, By Product Type,  2017 - 2028 (US$ Mn)
      • Market Size and Forecast, By Sample Type,  2017 - 2028 (US$ Mn)
      • Market Size and Forecast, By Test Type,  2017 - 2028 (US$ Mn)
      • Market Size and Forecast, By End User,  2017 - 2028 (US$ Mn)
      • Market Size and Forecast, By Country, 2017 – 2028, (US$ Mn)
        • U.S.
        • Canada
    • Latin America
      • Market Size and Forecast, By Product Type,  2017 - 2028 (US$ Mn)
      • Market Size and Forecast, By Sample Type,  2017 - 2028 (US$ Mn)
      • Market Size and Forecast, By Test Type,  2017 - 2028 (US$ Mn)
      • Market Size and Forecast, By End User,  2017 - 2028 (US$ Mn)
      • Market Size and Forecast, By Country, 2017 – 2028, (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Market Size and Forecast, By Product Type,  2017 - 2028 (US$ Mn)
      • Market Size and Forecast, By Sample Type,  2017 - 2028 (US$ Mn)
      • Market Size and Forecast, By Test Type,  2017 - 2028 (US$ Mn)
      • Market Size and Forecast, By End User,  2017 - 2028 (US$ Mn)
      • Market Size and Forecast, By Country, 2017 – 2028, (US$ Mn)
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Product Type,  2017 - 2028 (US$ Mn)
      • Market Size and Forecast, By Sample Type,  2017 - 2028 (US$ Mn)
      • Market Size and Forecast, By Test Type,  2017 - 2028 (US$ Mn)
      • Market Size and Forecast, By End User,  2017 - 2028 (US$ Mn)
      • Market Size and Forecast, By Country, 2017 – 2028, (US$ Mn)
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • Market Size and Forecast, By Product Type,  2017 - 2028 (US$ Mn)
      • Market Size and Forecast, By Sample Type,  2017 - 2028 (US$ Mn)
      • Market Size and Forecast, By Test Type,  2017 - 2028 (US$ Mn)
      • Market Size and Forecast, By End User,  2017 - 2028 (US$ Mn)
      • Market Size and Forecast, By Country, 2017 – 2028, (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Market Size and Forecast, By Product Type,  2017 - 2028 (US$ Mn)
      • Market Size and Forecast, By Sample Type,  2017 - 2028 (US$ Mn)
      • Market Size and Forecast, By Test Type,  2017 - 2028 (US$ Mn)
      • Market Size and Forecast, By End User,  2017 - 2028 (US$ Mn)
      • Market Size and Forecast, By Region/Country, 2017 – 2028, (US$ Mn)
        • South Africa
        • Central Africa
        • North Africa
  10. Competitive Landscape
    • Heat Map Analysis
    • Market Share Analysis
      • Abbott
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Hoffmann-La Roche AG
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Cardinal Health
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Alfa Scientific Designs Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Danaher
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Bio-Rad Laboratories Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Artron Laboratories Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Trinity Biotech
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • bioMérieux SA
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Creative Diagnostics
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • ACON Laboratories Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Thermo Fisher Scientific, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Sight Diagnostics Ltd.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Meridian Bioscience
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Quest Diagnostics
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Perkin Elmer, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Luminex Corporation
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Laboratory Corporation of America Holdings
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Veredus Laboratories
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
    • Analyst Views
  11. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 44 market data tables and 37 figures on "COVID-19 Rapid Diagnostic Test Market” - Global forecast to 2028

FAQgrowicon

Frequently Asked Questions

The global COVID-19 rapid diagnostic test market size is estimated to be valued at US$ 3,422.1 million in 2021 and is expected to exhibit a CAGR of 12.2% between 2021 and 2028.
Increasing incidence of COVID-19 and increasing research and development activities for the development of novel diagnostics for the diagnosis of COVID-19 infection are expected to drive the market growth over the forecast period.
Reagents & kits segment is expected to hold the major market share, owing to increasing product approvals and launches during the forecast period.
North America holds the largest market share in the market.
Major factors hampering growth of the market include product recalls, shortage of skilled healthcare professionals, and less efficacy of rapid COVID-19 diagnostic tests as compared to laboratory setting.
Major players operating in the market include Abbott, F. Hoffmann-La Roche AG, Cardinal Health, Alfa Scientific Designs Inc., Danaher, Bio-Rad Laboratories Inc., Artron Laboratories Inc., Trinity Biotech, bioMérieux SA, Creative Diagnostics, ACON Laboratories Inc., Thermo Fisher Scientific, Inc., Sight Diagnostics Ltd., Meridian Bioscience, Quest Diagnostics, Perkin Elmer, Inc., Luminex Corporation, Laboratory Corporation of America Holdings, and Veredus Laboratories.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner

Subscribe Newsletter

Kindly Subscribe for our latest news & articles.